SFN treatment has anti-obesity and antidiabetic effects through NRF2 activation in multiple models, such as diet-induced obese mice and rodents (6, 7, 8). The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.